Piribedil

Uses and Administration

Drug Profile

Piribedil is a non-ergot dopamine agonist that has been given orally in the treatment of parkinsonism ( Refer to ) and in circulatory disorders. Piribedil mesilate has been given by injection for circulatory disorders. Preparations of piribedil are licensed in some countries for the management of impaired memory and cognitive function in the elderly.

Adverse effects reported include nausea and vomiting, dizziness, hallucinations, confusion, drowsiness, hypothermia, dyskinesias, and occasional changes in liver function.

When used as monotherapy in Parkinson's disease a usual daily oral dose of piribedil is 150 to 250 mg in divided doses; a daily dose of 80 to 140 mg may be suitable when used as an adjunct to levodopa.

(last reviewed 2010-09-02; last modified 2010-01-20)

Effects on mental function

For reports of daytime somnolence occurring in patients receiving dopamine agonists including piribedil, see under Adverse Effects of Levodopa, Refer to .

For reference to disturbed behaviour includingexcessive gambling reported in patients with Parkinson's disease receiving dopamine agonists, see under Adverse Effects of Levodopa, Refer to .

For reference to dopamine dysregulation syndrome reported in patients with Parkinson's disease receiving dopamine agonists, see Abuse, under Precautions of Levodopa, Refer to .

(last reviewed 2010-09-02; last modified 2018-11-08)

Parkinsonism

Piribedil is a dopamine D2-agonist while its metabolite is reported to act on D1receptors. It has been mainly used as an adjunct to levodopa therapy in the treatment of Parkinson's disease ( Refer to ).

References.

(last reviewed 2010-09-02; last modified 2006-01-26)

References

1. Montastruc JL, et al.. Current status of dopamine agonists in Parkinson's disease management.Drugs. 1993; 46: 384–93. PubMed

2. Montastruc JL, et al.. A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease.Mov Disord. 1999; 14: 336–41. PubMed

3. Ziegler M, Rondot P. Activité du piribédil dans la maladie de Parkinson: étude multicentrique.Presse Med. 1999; 28: 1414–18. PubMed

4. Ziegler M, et al.. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.Mov Disord. 2003; 18: 418–25. PubMed

Preparations: Single-Ingredient

The following preparations list represents a compilation of all available salt forms or related substances for this drug product.

The symbol ¤ denotes a preparation which is discontinued or no longer actively marketed.

ARGENTINA: Trastoner; Trivastal;BRAZIL: Trivastal;CHINA: Trastal (泰舒达);FRANCE: Trivastal;GERMANY: Clarium; Trivastal¤;GREECE: Trivastal;INDIA: Trivastal;ITALY: Trivastan;MALAYSIA: Trivastal;PHILIPPINES: Trivastal;POLAND: Pronoran;PORTUGAL: Trivastal;RUSSIAN FEDERATION: Pronoran (Проноран);SINGAPORE: Trivastal;SPAIN: Circularina¤;THAILAND: Trivastal;TURKEY: Trivastal;UKRAINE: Pronoran (Проноран);VENEZUELA: Trivastal;

Therapeutic Use

• Antiparkinsonian Drugs

Last Updated 1/21/20